Fahd Adeeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fahd Adeeb has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Alexander Fraser
Rheumatology, University Hospital Limerick, Dooradoyle, Limerick, IRELAND
6 shared publicationsJoe Devlin
Rheumatology, University Hospital Limerick, Limerick, IRELAND
5 shared publicationsAustin G. Stack
Department of Nephrology, University Hospital Limerick, Limerick, Ireland
4 shared publicationsAlexander D. Fraser
Department of Rheumatology, University Hospital Limerick, Limerick, Ireland
3 shared publicationsAlexander Duncan Fraser
Department of Rheumatology, University Hospital Limerick, Limerick, Ireland; Graduate Entry Medical School, University of Limerick, Limerick, Ireland
3 shared publicationsAlwin Sebastian
Rheumatology, University Hospital Limerick, Limerick, IRELAND
3 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 21 (1) , 66
Correction: ERAS following spine surgery in the elderly: a systematic review and meta-analysis
- 31 January 2026
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 21 (1) , 66
Open AccessCorrection: ERAS following spine surgery in the elderly: a systematic review and meta-analysis
- Open Access
- 25 November 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1036
ERAS following spine surgery in the elderly: a systematic review and meta-analysis
As the global population ages, Enhanced Recovery After Surgery (ERAS) protocols have gained increasing importance for improving recovery, pain control, and
- 25 November 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1036
Open AccessERAS following spine surgery in the elderly: a systematic review and meta-analysis
As the global population ages, Enhanced Recovery After Surgery (ERAS) protocols have gained increasing importance for improving recovery, pain control, and
- Open Access
- 2 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70038
Lethal Gastrointestinal Manifestation and 3D ‐Reconstructive CT in Systemic Polyarteritis Nodosa ( PAN )
- 2 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70038
Open AccessLethal Gastrointestinal Manifestation and 3D ‐Reconstructive CT in Systemic Polyarteritis Nodosa ( PAN )
- 9 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (10) , e15366
Comment on: Coinciding Crohn's disease and polyarteritis nodosa: A sign of medically refractory disease?
- 9 October 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (10) , e15366
Comment on: Coinciding Crohn's disease and polyarteritis nodosa: A sign of medically refractory disease?
- Open Access
- 25 August 2021
- Published by IntechOpen
Lupus Nephritis: Current Updates
Lupus is a heterogenous multisystem autoimmune disease whereby nephritis is one of its most common cause of overall morbidity and mortality. Accurate, timely diagnosis and effective treatment in lupus nephritis (LN) remains a challenge to many clinicians including those who are directly involved in the daily care of these patients. Despite significant improvement in patients’ survival rate in recent years, in this era of precision medicine, there is pressing need to further improve our understanding and management of this disease. Our chapter would shed light on the key issues in LN including recent advances in our scientific understanding of its’ pathophysiology, major challenges and treatment strategies.
- 25 August 2021
- Published by IntechOpen
Open AccessLupus Nephritis: Current Updates
Lupus is a heterogenous multisystem autoimmune disease whereby nephritis is one of its most common cause of overall morbidity and mortality. Accurate, timely diagnosis and effective treatment in lupus nephritis (LN) remains a challenge to many clinicians including those who are directly involved in the daily care of these patients. Despite significant improvement in patients’ survival rate in recent years, in this era of precision medicine, there is pressing need to further improve our understanding and management of this disease. Our chapter would shed light on the key issues in LN including recent advances in our scientific understanding of its’ pathophysiology, major challenges and treatment strategies.
- 19 February 2021
- Vol. 39 Suppl 1 (1) , 31-32
Baricitinib plus leflunamide: a potentially dangerous combination?
- 19 February 2021
- Vol. 39 Suppl 1 (1) , 31-32
Baricitinib plus leflunamide: a potentially dangerous combination?
- 12 January 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Comment on: Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' by Giollo et al.
LER & CER: letter to Editor Rheumatology; Authors: D. Reffat, M. Dziedzic, A. O' Riordan, F. Adeeb
- 12 January 2021
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Comment on: Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' by Giollo et al.
LER & CER: letter to Editor Rheumatology; Authors: D. Reffat, M. Dziedzic, A. O' Riordan, F. Adeeb
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 4 (4) , 254-259
The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease
Objective: The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet’s disease (BD). Material and Methods: Patients with BD satisfying the International Study Group for Behçet’s Disease or the International Criteria for Behçet’s Disease criteria were recruited from a regional rheumatology program. The choice of anti-TNF, treatment response, and adverse events were specified. Response to treatment was evaluated by the detection of new, worsening, or improving clinical features, and management was benchmarked against current The European League against Rheumatism recommendations published in 2008. Results: Out of the total of 22 patients, 18 (81.9%) received anti-TNF therapies, resulting in 14 (77.8%) complete and 4 (22.2%) partial remissions. Eleven (61.1%) patients switched to a second anti-TNF, seven patients (38.9%) required three different anti-TNFs, and one required a fourth anti-TNF to achieve remission. Two patients required retrials before their disease was controlled. Anti-TNF therapy included infliximab (IFX): n=15, 83.3%; adalimumab (ADA): n=9, 50%; golimumab: n=6, 33.3%; etanercept: n=5, 27.8%; and certolizumab pegol: n=2, 11.1%. Secondary failure was observed with IFX (4/15; 26.7%) and ADA (2/9; 22.2%), and these (100%) were manifested after at least 2 years of treatment. Five patients with potentially life-threatening laryngeal involvement received anti-TNFs successfully halting disease progression. Five allergic reactions were encountered, and five serious infections were documented involving three patients aged ≥ 50 years, all with the use of IFX. Conclusion: Anti-TNF therapy induced a clinical response in 100% patients and achieved complete remission in 78% patients. It provides an effective alternative option for first-line therapy in severe BD where many conventional immunosuppressive therapies fail. Patients with BD who do not respond to one or more anti-TNFs because of intolerance, ineffectiveness, or secondary failure might benefit from switching to another drug from this group or even a retrial of a previously administered anti-TNF because unsatisfactory results with one biologic is not predictive of response to another anti-TNF. For those with potentially life-threatening destructive laryngeal manifestation, anti-TNF as a first choice may be considered. Cite this article as: Adeeb F, Ng WL, Khan MU, Devlin J, Stack AG, Fraser AD. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease. Eur J Rheumatol 2017; 4: 254-9.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 4 (4) , 254-259
Open AccessThe real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease
Objective: The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet’s disease (BD). Material and Methods: Patients with BD satisfying the International Study Group for Behçet’s Disease or the International Criteria for Behçet’s Disease criteria were recruited from a regional rheumatology program. The choice of anti-TNF, treatment response, and adverse events were specified. Response to treatment was evaluated by the detection of new, worsening, or improving clinical features, and management was benchmarked against current The European League against Rheumatism recommendations published in 2008. Results: Out of the total of 22 patients, 18 (81.9%) received anti-TNF therapies, resulting in 14 (77.8%) complete and 4 (22.2%) partial remissions. Eleven (61.1%) patients switched to a second anti-TNF, seven patients (38.9%) required three different anti-TNFs, and one required a fourth anti-TNF to achieve remission. Two patients required retrials before their disease was controlled. Anti-TNF therapy included infliximab (IFX): n=15, 83.3%; adalimumab (ADA): n=9, 50%; golimumab: n=6, 33.3%; etanercept: n=5, 27.8%; and certolizumab pegol: n=2, 11.1%. Secondary failure was observed with IFX (4/15; 26.7%) and ADA (2/9; 22.2%), and these (100%) were manifested after at least 2 years of treatment. Five patients with potentially life-threatening laryngeal involvement received anti-TNFs successfully halting disease progression. Five allergic reactions were encountered, and five serious infections were documented involving three patients aged ≥ 50 years, all with the use of IFX. Conclusion: Anti-TNF therapy induced a clinical response in 100% patients and achieved complete remission in 78% patients. It provides an effective alternative option for first-line therapy in severe BD where many conventional immunosuppressive therapies fail. Patients with BD who do not respond to one or more anti-TNFs because of intolerance, ineffectiveness, or secondary failure might benefit from switching to another drug from this group or even a retrial of a previously administered anti-TNF because unsatisfactory results with one biologic is not predictive of response to another anti-TNF. For those with potentially life-threatening destructive laryngeal manifestation, anti-TNF as a first choice may be considered. Cite this article as: Adeeb F, Ng WL, Khan MU, Devlin J, Stack AG, Fraser AD. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease. Eur J Rheumatol 2017; 4: 254-9.
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 3 (2) , 73-74
Janus kinase 2 V617F mutation and thrombotic events in Behcet’s disease: The Alexandria experience
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 3 (2) , 73-74
Open AccessJanus kinase 2 V617F mutation and thrombotic events in Behcet’s disease: The Alexandria experience